

B. Amendment of Claims

-- Please cancel claims 42, 43 and 50-96 without prejudice.

33. (Amended) An isolated polypeptide including an antigen binding site, the polypeptide comprising:

Ε1 (a) two variable domains, each variable domain independently sequence comprising at least one group of three complementarity determining regions (CDRs) interposed between framework regions (FRs), which variable domains are linked a polypeptide linker to form a single polypeptide chain in which said framework and complementarity determining regions together defining a variable region binding domain which can be immunologically reactive with an antigen, and

(b) a third amino acid sequence, being part of said single polypeptide chain, having a biological activity independent of said immunologically reactivity.

97. (new) The polypeptide of claim 33, wherein said framework regions are derived from human immunoglobulin sequences.

98. (new) The polypeptide of claim 33, wherein at some of said complementarity determining regions are derived from human immunoglobulin sequences.

99. (new) The polypeptide of claim 33, wherein said variable domains are derived from human immunoglobulin sequences.

DVP 100. (new) The polypeptide of claim 33, wherein at some of said complementarity determining regions a derived from human immunoglobulin sequences.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

33. (Amended) An isolated polypeptide including an ~~for binding preferentially to a c-erbB-2 or a c-erbB-2-related tumor-antigen~~ binding site, the polypeptide comprising: